Canada markets open in 6 hours 42 minutes

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6000+0.0100 (+0.63%)
At close: 04:00PM EDT
1.7000 +0.10 (+6.25%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.5900
Open1.6500
Bid0.0000 x 1800
Ask0.0000 x 800
Day's Range1.5520 - 1.7000
52 Week Range1.1400 - 5.4400
Volume2,719,475
Avg. Volume1,433,193
Market Cap317.542M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.4600
Earnings DateMar 24, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.88
  • GlobeNewswire

    atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

    atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditionsContinued operational progress on robust clinical pipeline, with multiple phase 1 and phase 2 proof-of-concept datasets expected in the next two years$273 million in cash, cash equivalents and short-term investments at end of 2022 and access to a term loan facility of up to an additional $160 million provide anticipated

  • GlobeNewswire

    atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

    RL-007: First patient dosed in the on-going phase 2b study in cognitive impairment associated with schizophreniaGRX-917: Intention to progress GRX-917 into a phase 2 study in an anxiety disorder as the next step in clinical developmentCOMP360: Recently announced acceleration of the Pivotal Trial 1 (COMP 005) part of the phase 3 program, with top line data now expected in the summer of 2024Corporate: As a result of our recent restructuring and pipeline updates, the company has extended its cash r

  • GlobeNewswire

    atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

    NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference. Details of the company’s panel participation are as follows: Cowen 43rd Annual Health Care Conference Format: Neuropsych Corporate Panel Date and Time: Monday, March 6th, 12:50 p.m. – 1:20 p.m. ET Location: Boston, MA A live webc